StreetInsider.com News Articles

Protara completes enrollment in THRIVE-3 Phase 2b trial

Thu, 15 Oct 2026 08:00:52 -0400

Protara Therapeutics, Inc. (Nasdaq: TARA) announced it has completed enrollment of the Phase 2b, open-label dose confirmation phase of its THRIVE-3 clinical trial, which is evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS).

The Phase 2b portion of the trial enrolled 24 patients and is designed to evaluate the safety and pharmacokinetics of IV Choline Chloride across multiple doses and to select doses for continued evaluation. The company said it expects to report interim results from this cohort in the fourth quarter of 2026.

THRIVE-3 is a registrational, seamless Phase 2b/3 clinical trial. The

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

Thu, 15 Oct 2026 08:00:00 -0400

Company remains on track to report interim results from Phase 2b cohort in 4Q 2026

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS). The dose confirmation phase of the trial includes 24 patients.

“We are excited about

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

Thu, 15 Oct 2026 08:00:00 -0400

Company remains on track to report interim results from Phase 2b cohort in 4Q 2026

“We are excited about

Protara Therapeutics (TARA) Reiterated at Overweight by Cantor Fitzgerald After Management Meet

Thu, 15 Oct 2026 07:54:50 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Protara Therapeutics (NASDAQ: TARA).

The analyst commented, "We hosted Protara management (CEO Jesse Shefferman, CFO Pat Fabbio, Chief R&D Officer Jackie Zummo, CCO Bill Conkling, and Head of IR Justine O’Malley) for a very engaging and informative investor dinner yesterday (10/13). While discussions centered on TARA-002 (bacterial immune potentiator) in high-risk non-muscle invasive bladder cancer (NMIBC), there was also a fair amount of good interactions on TARA-002's market potential in lymphatic malformations (LMs), and the upcoming 4Q26 THRIVE-3 IV Choline readout. We share investors’ frustration. At a ~$160M market cap, Protara

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919261.html

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919261.html

Form S-8 Protara Therapeutics,

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905954.html

Form S-8 Protara Therapeutics,

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905954.html

Protara Therapeutics, Inc. (TARA) Misses Q2 EPS by 2c

Tue, 11 Aug 2026 09:36:48 -0400

Protara Therapeutics, Inc. (NASDAQ: TARA) reported Q2 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Protara Therapeutics, Inc. (TARA) click here.

Form 10-Q Protara Therapeutics, For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901944.html

Form 10-Q Protara Therapeutics, For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901944.html

Form 8-K Protara Therapeutics, For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901911.html

Form 8-K Protara Therapeutics, For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901911.html

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV